Abstract:BACKGROUND: Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their limited effectiveness in accordance with the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with improved outcome, such as immunotherapy that utilizes and enhances the normal capacity of the patient's immune system.METHODS: Chimeric Antigen Receptor (CAR) T-cell therapy involves genetic modification of patient's autologous T-cells to express a CAR specific for a tumor antigen, following by ex vivo cell expansion and re-infusion back to the patient. CARs are fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. This T-cell genetic modification may occur either via viral-based gene transfer methods or nonviral methods, such as DNA-based transposons, CRISPR/Cas9 technology or direct transfer of in vitro transcribed-mRNA by electroporation.RESULTS: Clinical trials have shown very promising results in end-stage patients with a full recovery of up to 92% in Acute Lymphocytic Leukemia. Despite such results in hematological cancers, the effective translation of CAR T-cell therapy to solid tumors and the corresponding clinical experience is limited due to therapeutic barriers, like CAR T-cell expansion, persistence, trafficking, and fate within tumors.CONCLUSION: In this review, the basic design of CARs, the main genetic modification strategies, the safety matters as well as the initial clinical experience with CAR T-cells are described.

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

CAR-T cell therapy: current limitations and potential strategies

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Prospects and challenges for use of CAR T cell therapies in solid tumors

Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Methodology, Applications and Advancements of Car-T Cell Therapy in Malignancies

CAR-T cell therapy: a game-changer in cancer treatment and beyond

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

CAR T-Cell Therapy: Progress and Prospects

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

CAR T-cell immunotherapy: The path from the by-road to the freeway?